# Glaxosmithkline (Finland)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/glaxosmithkline-finland/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 46 |
| Citations | 12,778 |
| City | Espoo |
| Country | FI |
| Description | Glaxosmithkline (Finland) is a research organisation in Espoo, FI. OpenAlex records 312 works and 12,778 citations for it. 146 researchers list it as their most recent affiliation. |
| Homepage | http://fi.gsk.com/ |
| OpenAlex ID | https://openalex.org/I4210115161 |
| Researchers | 146 |
| ROR ID | https://ror.org/01jxkq910 |
| Type | company |
| Works | 312 |

## University papers

- [Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-belimumab-in-patients-with-active-systemic-lupus/)
- [Catastrophic Antiphospholipid Syndrome: Clinical and Laboratory Features of 50 Patients](https://scholariq.org/papers/catastrophic-antiphospholipid-syndrome-clinical-and-laboratory-features-of-50/)
- [Anti-inflammatory and immunosuppressive drugs and reproduction.](https://scholariq.org/papers/anti-inflammatory-and-immunosuppressive-drugs-and-reproduction/)
- [Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double‐blind, placebo‐controlled trial in asymptomatic antiphospholipid antibody–positive individuals](https://scholariq.org/papers/aspirin-for-primary-thrombosis-prevention-in-the-antiphospholipid-syndrome-a/)
- [Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study](https://scholariq.org/papers/hydroxychloroquine-hcq-in-lupus-pregnancy-double-blind-and-placebo-controlled/)
- [Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study](https://scholariq.org/papers/celecoxib-versus-naproxen-and-diclofenac-in-osteoarthritis-patients-success-i/)
- [Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression](https://scholariq.org/papers/systemic-lupus-erythematosus-lupus-nephritis-and-end-stage-renal-disease-a/)
- [Real-World Immunosuppressant Treatment Patterns for Patients with Lupus Nephritis in the United States](https://scholariq.org/papers/real-world-immunosuppressant-treatment-patterns-for-patients-with-lupus/)

## University researchers

- [Roger A. Levy](https://scholariq.org/researchers/roger-a-levy/)

## University top topics

Showing 8 of 25.

- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)
- [Inhalation and Respiratory Drug Delivery](https://scholariq.org/topics/inhalation-and-respiratory-drug-delivery/)
- [Respiratory and Cough-Related Research](https://scholariq.org/topics/respiratory-and-cough-related-research/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Eosinophilic Disorders and Syndromes](https://scholariq.org/topics/eosinophilic-disorders-and-syndromes/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)
- [Pneumonia and Respiratory Infections](https://scholariq.org/topics/pneumonia-and-respiratory-infections/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.